Concepedia

Kimberly Maxfield

KM

11

Publications

735

Citations

11

H-Index

2009

Active since

Affiliations

United States Food and Drug Administration(Current)

Pfizer (United States)

Bristol-Myers Squibb (United States)

Sanofi (United States)

Takeda (United States)

Kimberly Maxfield is an author at United States Food and Drug Administration specializing in medicine, cell biology, and engineering.

Top concepts

Publications per year

2009–2024

11

Publications

11

Thin-Walled Microvessels in Human Coronary Atherosclerotic Plaques Show Incomplete Endothelial Junctions

Judith C. Sluimer, Frank D. Kolodgie, Ann Pascale Bijnens et al. · Journal of the American College of Cardiology · 2009 · 359 citations · Full text

, , +12

Comprehensive functional characterization of cancer–testis antigens defines obligate participation in multiple hallmarks of cancer

Kimberly Maxfield, Patrick Taus, Kathleen Corcoran et al. · Nature Communications · 2015 · 122 citations · Full text

Multiple Cancer Testis Antigens Function To Support Tumor Cell Mitotic Fidelity

Kathryn M. Cappell, Rebecca Sinnott, Patrick Taus et al. · Molecular and Cellular Biology · 2012 · 75 citations · Full text

, , +17

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations

Elizabeth S. Duke, Liza Stapleford, Nicole Drezner et al. · Clinical Cancer Research · 2022 · 36 citations · Full text

2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 &amp; CAR-T Immunogenicity; PCR &amp; Vaccine Assay Performance; ADA Assay Comparability &amp; Cut Point Appropriateness ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)

LiNa Loo, Shannon Harris, Mark Milton et al. · Bioanalysis · 2022 · 33 citations

, , +31

Rows per page

1–5 of 11